ANZCTR search results

Lately, a new method for intraarticular hip injection has been increasingly considered, and is believed to be very accurate, eliminating the need for imaging assistance (which enables the surgeon to apply the treatment in an outpatient environment). This blind method of injection will be assessed by: 1. Injecting small amount of air into the hip prior to hip arthroscopy surgery in the operating theatre, in the same technique as it is performed on a regular basis, but via a different approach (anterior versus lateral) and initially with no image assistance. The location of the needle will then be assessed using fluoroscopy. 2. Injecting small amount of Methylene Blue into the hip prior to total hip replacement surgery, verifying its location and injection accuracy later during the same operation. Our hypothesis is that anterior hip injection technique, without imaging guidance, would yield high accuracy rates. Hip injections able to be performed without imaging will also lead to less expense for the patient and community with a reduction in burden on imaging services.

This trial will be looking at patients who have osteoarthritis of the knee. Such patients will be referred by their doctor for knee arthroscopy. These patients usually have mild-moderate osteoarthritis of the knee and will undergo arthroscopy to reduce their pain and improve function. At the moment, when the arthroscopy is performed, a certain fluid pressure is used. This trial will try using a lower pressure and compare it with the current standard. It is hypothesised that patients who get the lower pressure will have less pain, less bone marrow swelling and increased degree of function. These are the three areas the trial will be assessing and will be comparing this with patients who get the current standard pressure, 6 weeks after the arthroscopy.

This study aims to assess whether the side of the body that a central venous line is inserted affects the risk of developing a bloodstream infection in cancer patients. Who is it for? You may be eligible to join this study if you are a cancer patient aged 15 years or above, who needs to have a central venous access device (CVAD) inserted. Trial details Participants in this trial will be randomly (by chance) allocated to one of two groups. Participants in one group will have the CVAD inserted into their dominant arm (i.e. right arm in right-handed people and left arm in left-handed people). Participants in the other group will have the CVAD inserted into their non-dominant arm. There will be no other change to treatment provided. Participants will be monitored to determine the incidence of catheter-associated bloodstream infection (CA-BSI) and catheter-related bloodstream infection (CR-BSI). This will enable us to find out whether the increased movement of the dominant arm might increase the risk of infection.

A study to test the efficacy and safety of investigational therapy MK-8931 in the treatment of mild to moderate Alzheimer's Disease

The purpose of this study is to investigate whether nasal irrigation with a topical corticosteroid (mometasone) additive, is more beneficial in controlling the symptoms of chronic rhinosinusitis (CRS) post-operatively, than the treatments currently used. Irrigation with with a solution that contains mometasone may provide better control of CRS symptoms, compared to the simple intranasal steroid sprays that are currently used in conjunction with salt water irrigation. Patients undergoing endoscopic sinus surgery as part of the management of their CRS are eligible to participate. Patients who choose to participate in the study will be randomly allocated to one of two treatment groups. This is a double-blinded trial, so neither the patient, nor the patient's treating surgeon will know which treatment group the patient has been allocated to.

This evaluation trial will evaluate a brief parent Lifestyle Triple P Seminar program for parents of overweight children aged 3 – 10 years of age in a randomised trial comparing the parenting intervention against care as usual. The CONSORT guidelines for randomised controlled trials will be utilised. The study is a 2 (Triple P vs case as usual) x 4 (time: pre-test, post-test, 6-month follow up, and 12-month follow up) design. The study will experimentally test the relative impact of Triple P against care as usual in improving both general and lifestyle-specific child and parenting outcomes. The trial is recruiting all over Brisbane and Ipswich suburbs.

This is a study aiming to evaluate whether metformin, an antidiabetic medication, can be used safety and effectively in patients with type 2 diabetes who are receiving peritoneal dialysis for their end stage kidney disease. The study runs over 4 weeks of active treatment, 250mg of metformin daily orally. We hypothesise that metformin can be safely used in patients with type 2 diabetes with end stage renal failure if dosed based on predicted drug clearance.

The study aims to analyse the effect of cooling, combined pre-cooling and cooling during exercise, in cycling with a passive cooling vest on core body temperature, heart rate, balance, physical capacity and fatigue of individuals with MS and general people.

Air is currently used as the insufflation agent during colonoscopy to allow for visualisation & detection of colorectal lesions. Recently, there has been a trend towards introducing carbon dioxide as an alternative agent as this reportedly reduces post-procedural discomfort. There have been several trials internationally that have revealed this trend, but none so far in Australia. Our aim is to randomise adult patients with intact colons (those who have not undergone any bowel resection) to either air and carbon dioxide with the aim of assessing and comparing their post-procedural discomfort using a visual analog scale from 0 to 10. Other information such as the time to completion of the procedure and time to reach the end of the colon (that is the caecum) will be obtained. We propose that the use of carbon dioxide as the insufflation agent during colonoscopy is better in terms of improvement of post-procedural discomfort than air.

Intrauterine growth restriction is the term used to describe a condition where an unborn baby does not reach its optimum size. In the short and long term, intrauterine growth restricted babies have a higher risk of serious disease and even death. It is well established that very low levels of oxygen in the baby's blood can harm the baby's health through a state known as oxidative stress. Currently, there is no established treatment available to treat intrauterine growth restriction or its complications. In experimental animal studies however, the naturally occuring hormone, melatonin, has been shown to significantly reduce oxidative stress and improve health of the unborn babies that have suffered from intrauterine growth restriction. This study aims to find out if the use melatonin twice per day throughout pregnancies affected by intrauterine growth restriction will lower the level of oxidative stress experienced by the unborn baby. If this is the case melatonin may help protect the unborn baby from damage caused by oxidative stress, this will be studied in a separate future study.